Vieitez J M, Martín Algarra S, Muñoz L, Fernández Hidalgo O, Herranz P, Azinovick I, Zornoza G
Departamento de Oncología Médica, Clínica Universitaria de Navarra, Pamplona.
Rev Med Univ Navarra. 1990 Jul-Sep;34(3):172-5.
From 1982 to 1989, 68 patients were treated with the diagnosis of breast cancer. 57 were premenopausal and 11 postmenopausal. The most frequent stage was T2N1 (44.1%) followed by T1N1 (20.6%). The mean dosage of chemotherapy given were 91.2% for cyclophosphamide, 88% for methotrexate and 94% for 5-fluorouracil. The treatment was well tolerated and the most frequent toxicity encountered was leukopenia. The disease free survival were 89.4% at 96 month for premenopausal and 63.3% at 68 month for postmenopausal. We have not seen any differences in the disease free survival in relation to the size of the tumor or the status of the hormonal receptors of the tumor. The most important prognostic factor were the number of positive axilar nodes affected and the dosage of chemotherapy.
1982年至1989年期间，68例患者被诊断为乳腺癌并接受治疗。其中57例为绝经前患者，11例为绝经后患者。最常见的分期是T2N1（44.1%），其次是T1N1（20.6%）。环磷酰胺的化疗平均给药剂量为91.2%，甲氨蝶呤为88%，5-氟尿嘧啶为94%。治疗耐受性良好，最常见的毒性反应是白细胞减少。绝经前患者96个月时的无病生存率为89.4%，绝经后患者68个月时的无病生存率为63.3%。我们未发现无病生存率与肿瘤大小或肿瘤激素受体状态之间存在差异。最重要的预后因素是受影响的腋窝阳性淋巴结数量和化疗剂量。
